Traws Pharma (NASDAQ:TRAW) Stock Price Down 3.5% – Here’s Why

Traws Pharma, Inc. (NASDAQ:TRAW) shares were down 3.5% during mid-day trading on Tuesday . The stock traded as low as $1.0514 and last traded at $1.09. Approximately 137,511 shares changed hands during trading, a decline of 66% from the average daily volume of 399,087 shares. The stock had previously closed at $1.13.

Analyst Ratings Changes

A number of analysts recently weighed in on TRAW shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Traws Pharma in a report on Monday, December 22nd. Wall Street Zen cut shares of Traws Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. HC Wainwright initiated coverage on Traws Pharma in a report on Wednesday, December 3rd. They set a “buy” rating and a $8.00 price target on the stock. Finally, Zacks Research upgraded Traws Pharma to a “hold” rating in a research report on Thursday, December 4th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Traws Pharma Stock Performance

The business’s 50 day moving average price is $2.11 and its two-hundred day moving average price is $1.90. The company has a market capitalization of $8.71 million, a price-to-earnings ratio of 0.01 and a beta of 1.74.

Traws Pharma (NASDAQ:TRAW) last announced its earnings results on Thursday, November 13th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 2,883.04% and a net margin of 3,028.25%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TRAW. Two Sigma Investments LP raised its position in Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after acquiring an additional 5,955 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Traws Pharma by 133.3% in the 1st quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock worth $402,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Traws Pharma in the 1st quarter worth approximately $759,000. Institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.